The hope and reality of long-acting hemophilia products

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

US Biosimilar Pathway Unlikely to be Used†

(2011) Claudia Wiatr   BIODRUGS

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

(2011) H. Ostergaard et al.   BLOOD

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients

(2011) A. D. Shapiro et al.   BLOOD

Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B

(2011) C. Negrier et al.   BLOOD

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

(2011) E. K. Waters et al.   BLOOD

Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review

(2011) Massimo Franchini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Biosimilars of Biological Drug Therapies

(2011) George Dranitsaris et al.   DRUGS

A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing

(2011) S. BJÖRKMAN   HAEMOPHILIA

A study of reported factor IX use around the world

(2011) J. S. STONEBRAKER et al.   HAEMOPHILIA

Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008

(2011) S. GUH et al.   HAEMOPHILIA

Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008

(2011) S. GUH et al.   HAEMOPHILIA

Successful long-term replacement therapy with FXIII concentrate (Fibrogammin® P) for severe congenital factor XIII deficiency: a prospective multicentre study

(2011) M. DREYFUS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Concentrate-related inhibitor risk: is a difference always real?

(2011) A. IORIO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies

(2011) L. M. ALEDORT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII

(2011) L. M. ALEDORT et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII inhibitors in previously treated hemophilic patients

(2011) P. M. MANNUCCI   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Functional factor VIII made with von Willebrand factor at high levels in transgenic milk

(2011) S. W. PIPE et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects

(2011) J. MØSS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

(2011) Lacramioara Ivanciu et al.   NATURE BIOTECHNOLOGY

Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B

(2011) Amit C. Nathwani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment ofvon Willebrand Factor Propeptide Improves the Diagnosis ofvon Willebrand Disease

(2011) Alessandra Casonato et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

(2010) Katrin Knop et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Improved recombinant protein yield using a codon deoptimized DHFR selectable marker in a CHEF1 expression plasmid

(2010) Amy D. Westwood et al.   BIOTECHNOLOGY PROGRESS

Prolonged activity of factor IX as a monomeric Fc fusion protein

(2010) R. T. Peters et al.   BLOOD

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Special lectures in haemophilia management

(2010) A. BATOROVA et al.   HAEMOPHILIA

Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report

(2010) J. ASTERMARK et al.   HAEMOPHILIA

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

(2010) P. W. COLLINS et al.   HAEMOPHILIA

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

(2010) S. BJÖRKMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Future directions in hemostasis: Normalizing the lives of patients with hemophilia

(2010) Marcus E. Carr   THROMBOSIS RESEARCH

Progress in the treatment of bleeding disorders

(2010) Garrett E. Bergman   THROMBOSIS RESEARCH

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice

(2009) J. Pan et al.   BLOOD

Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years

(2009) Sven Björkman et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Prophylactic therapy with Fibrogammin®P is associated with a decreased incidence of bleeding episodes: a retrospective study

(2009) J. LUSHER et al.   HAEMOPHILIA

A study of reported factor VIII use around the world

(2009) J. S. STONEBRAKER et al.   HAEMOPHILIA

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

(2009) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients

(2009) Kathelijn Fischer et al.   PLoS One

WFH – the cornerstone of global development: 45 years of progress

(2008) M. W. SKINNER   HAEMOPHILIA

Back to the future: a recent history of haemophilia treatment

(2008) P. M. MANNUCCI   HAEMOPHILIA

Haemophilia care then, now and in the future

(2008) J. OLDENBURG et al.   HAEMOPHILIA

Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A

(2008) J. S. POWELL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects

(2008) J. MØSS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Extending half-life in coagulation factors: where do we stand?

(2008) David Lillicrap   THROMBOSIS RESEARCH

Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

(2008) Stefan Schulte   THROMBOSIS RESEARCH

Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A

(2007) S. Prasad et al.   BLOOD